{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:40Z","timestamp":1791227800748,"version":"4.1.0"},"reference-count":73,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) is characterized not only by chronic hyperglycemia but also by profound adipose tissue dysfunction, including impaired lipid handling, low-grade inflammation, mitochondrial dysfunction, and extracellular matrix (ECM) remodeling. These adipose tissue alterations play a central role in the development of systemic insulin resistance, ectopic lipid accumulation, and cardiometabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly semaglutide, have emerged as highly effective therapies for T2DM and obesity. While their glucose-lowering and appetite-suppressive effects are well established, accumulating evidence indicates that semaglutide exerts pleiotropic metabolic actions that extend beyond glycemic control, with adipose tissue representing a key target organ. This review synthesizes current preclinical and clinical evidence on the molecular and cellular mechanisms through which semaglutide modulates adipose tissue biology in T2DM. We discuss depot-specific effects on visceral and subcutaneous adipose tissue, regulation of adipocyte lipid metabolism and lipolysis, enhancement of mitochondrial biogenesis and oxidative capacity, induction of beige adipocyte programming, modulation of adipokine and cytokine secretion, immunometabolic remodeling, and attenuation of adipose tissue fibrosis and ECM stiffness. Collectively, available data indicate that semaglutide promotes a functional shift in adipose tissue from a pro-inflammatory, lipid-storing phenotype toward a more oxidative, insulin-sensitive, and metabolically flexible state. These adipose-centered adaptations likely contribute to improvements in systemic insulin sensitivity, reduction in ectopic fat deposition, and attenuation of cardiometabolic risk observed in patients with T2DM. Despite compelling mechanistic insights, much of the current evidence derives from animal models or in vitro systems. Human adipose tissue-focused studies integrating molecular profiling, advanced imaging, and longitudinal clinical data are therefore needed to fully elucidate the extra-glycemic actions of semaglutide and to translate these findings into adipose-targeted therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms27031186","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:14:23Z","timestamp":1769415263000},"page":"1186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control"],"prefix":"10.3390","volume":"27","author":[{"given":"Tatjana","family":"\u00c1bel","sequence":"first","affiliation":[{"name":"Department of Dietetics and Nutritional Sciences, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Csobod Csajb\u00f3kn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Dietetics and Nutritional Sciences, Faculty of Health Sciences, Semmelweis University, 1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2147\/DMSO.S524000","article-title":"Investigating the pathogenesis and treatment of type 2 diabetes mellitus from the perspective of adipose tissue","volume":"18","author":"Kang","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Alloca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Di Maio, G., Monda, M., and La Marra, M. (2025). Endocrine and metabolic mechanisms linking obesity to type 2 diabetes: Implications for targeted therapy. Healthcare, 16.","DOI":"10.3390\/healthcare13121437"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cimini, F.A., Sentinelli, F., Oldani, A., Barchetta, I., and Cavallo, M.G. (2025). Adipose tissue dysfunction and metabolic diseases: The role of vitamin D\/vitamin D receptor axis. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202509.1434.v1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1111\/dom.15911","article-title":"Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the all of US program","volume":"26","author":"Mayer","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112910","DOI":"10.1016\/j.diabres.2025.112910","article-title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: Emulation of a target trial","volume":"229","author":"Sklepinski","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e62667","DOI":"10.2196\/62667","article-title":"Effect of semaglutide on physical function, body composition, and biomarkers of aging in older adults with overweight and insulin resistance: Protocol for an open-labeled randomized controlled trial","volume":"13","author":"Cortes","year":"2024","journal-title":"JMIR Res. Protoc."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., and Sabb\u00e0, C. (2023). Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: A 26-week prospective real-life study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1240263"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem. Funct."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s13679-025-00660-w","article-title":"Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs","volume":"14","author":"Villarroya","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102126","DOI":"10.1016\/j.molmet.2025.102126","article-title":"Semaglutide and bariatric surgery induce distinct changes in the composition of mouse white adipose tissue","volume":"95","author":"Emont","year":"2025","journal-title":"Mol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Horwitz, A., and Birk, R. (2023). Adipose tissue hyperplasia and hypertrophy in common and syndromic obesity\u2014The case of BBS obesity. Nutrients, 15.","DOI":"10.3390\/nu15153445"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dommel, S., and Bl\u00fcher, M. (2021). Does C-C motif chemokine ligand 2 (CCL2) link obesity to a pro-inflammatory state?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031500"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zatterale, F., Longo, M., Naderi, J., Raciti, G.A., Desiderio, A., Miele, C., and Beguinot, F. (2020). Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.01607"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1002\/j.2040-4603.2023.tb00254.x","article-title":"Extracellular matrix (ECM) and fibrosis in adipose tissue: Overview and perspectives","volume":"13","author":"Sun","year":"2023","journal-title":"Compr. Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e240115","DOI":"10.1530\/JOE-24-0115","article-title":"The role of adipose tissue dysfunction in hepatic insulin resistance and T2D","volume":"262","author":"Sancar","year":"2024","journal-title":"J. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"An, Q., Zhang, Q.H., Wang, Y., Zhang, H.Y., Liu, Y.H., Zhang, Z.T., Zhang, M.L., Lin, L.J., He, H., and Yang, Y.F. (2024). Association between type 2 diabetes mellitus and body composition based on MRI fat fraction mapping. Front. Public. Health, 12.","DOI":"10.3389\/fpubh.2024.1332346"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s44324-024-00036-z","article-title":"Human adipose depots\u2019 diverse functions and dysregulations during cardiometabolic disease","volume":"2","author":"Ziegler","year":"2024","journal-title":"npj Metab. Health Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jouy, S.H., Mohan, S., Scichilone, G., Mostafa, A., and Mahmoud, A.M. (2024). Adipokines in the crosstalk between adipose tissues and other organs: Implications in cardiometabolic diseases. Biomedicines, 12.","DOI":"10.3390\/biomedicines12092129"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rabiee, A., Hossain, M.A., and Poojari, A. (2025). Adipose tissue insulin resistance: A key driver of metabolic syndrome pathogenesis. Biomedicines, 13.","DOI":"10.3390\/biomedicines13102376"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical Pharmacokinetics of Semaglutide: A Systematic Review","volume":"25","author":"Yang","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tamayo-Trujillo, R., Ruiz-Pozo, V.A., Cadena-Ullauri, S., Guevara-Ram\u00edrez, P., Paz-Cruz, E., Zambrano-Villacres, R., Simancas-Racines, D., and Zambrano, A.K. (2024). Molecular mechanisms of semaglutide and liraglutide as therapeutic option for obesity. Front. Nutr., 11.","DOI":"10.3389\/fnut.2024.1398059"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Szekeres, Z., Nagy, A., Jahner, K., and Szabados, E. (2024). Impact of selected glucagon-like peptide-1 receptor agonists on serum lipids, adipose tissue, and muscle metabolism\u2014A narrative review. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158214"},{"key":"ref_28","first-page":"212585","article-title":"Clinical potential of treatment with semaglutide in type 2 diabetes patients","volume":"8","year":"2019","journal-title":"Drugs Context"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: A new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/dom.14863","article-title":"Semaglutide for treatment of overweight and obesity: A review","volume":"25","author":"Bergmann","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Gong, B., Li, C., Shi, T., Wang, F., Dai, R., Chen, G., and Su, H. (2025). GLP-1 receptor agonists: Exploration of transformation from metabolic regulation to multi-organ therapy. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1675552"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am. J. Prev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.70141","article-title":"Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study","volume":"28","author":"Alissou","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vozza, A., Triggiani, D., Fanelli, M., Lisco, G., Coletto, D., Custodero, C., Volpe, S., Racaniello, D., Colaianni, V., and Lavarra, V. (2025). Predictive factors of body weight loss in patients with type 2 diabetes treated with GLP-1 receptor agonists: A 52-week prospective real-life study. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1674308"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once weekly in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.13005\/bpj\/3192","article-title":"Effect of semaglutide add-on to metformin on visceral adiposity index and markers of visceral adipose tissue activity in type 2 diabetic patients","volume":"18","author":"Shaheer","year":"2025","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hropot, T., Herman, R., Janez, A., Lezaic, L., and Jensterle, M. (2023). Brown adipose tissue: A new potential target for glucacon-like peptide 1 receptor agonists in the treatment of obesity. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108592"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Zhu, R.Y., and Chen, S. (2023). Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1095432"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1038\/s41467-024-52258-w","article-title":"Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system","volume":"15","author":"Qi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gamberi, T., Magherini, F., Modesti, A., and Fiaschi, T. (2018). Adiponectin signaling pathways in liver diseases. Biomedicines, 6.","DOI":"10.3390\/biomedicines6020052"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sun, L., Shang, B., Lv, S., Liu, G., Wu, Q., and Geng, Y. (2025). Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1562896"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Soto-Catal\u00e1n, M., Opazo-R\u00edos, L., Quiceno, H., L\u00e1zaro, I., Moreno, J.A., G\u00f3mez-Guerrero, C., Egido, J., and Mas-Fontao, S. (2024). Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052961"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Dusilov\u00e1, T., Kov\u00e1\u0159, J., La\u0148kov\u00e1, I., Thieme, L., Hub\u00e1\u010dkov\u00e1, M., \u0160ediv\u00fd, P., Pajuelo, D., Burian, M., Dezortov\u00e1, M., and Mil\u00e1nkov\u00e1, D. (2024). Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD). J. Clin. Med., 13.","DOI":"10.3390\/jcm13206100"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tem.2024.08.002","article-title":"Subcutaneous adipose tissue and skeletal muscle mitochondria following weight loss","volume":"36","author":"Pirinen","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","author":"Xu","year":"2016","journal-title":"Diabetologia"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kononova, Y.A., Tuchina, T.P., and Babenko, A.Y. (2024). Brown and beige adipose tissue: One or different targets for treatment of obesity and obesity-related metabolic disorders?. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252413295"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Masson, W., Lobo, M., Nogueira, J.P., Rodriguez-Granillo, A.M., Barbagelata, L.E., and Siniawski, D. (2024). Anti-inflammatory effect of semaglutide: Updated systematic review and meta-analysis. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1379189"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2017.90","article-title":"Adapting to obesity with adipose tissue inflammation","volume":"13","author":"Reilly","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucacon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cmet.2013.06.016","article-title":"Fibrosis and adipose tissue dysfunction","volume":"18","author":"Sun","year":"2013","journal-title":"Cell Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/MCB.01300-08","article-title":"Metabolic dysregulation and adipose tissue fibrosis: Role of collagen VI","volume":"29","author":"Khan","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/adip.19752","article-title":"Peri-adipocyte ECM remodeling in obesity and adipose tissue fibrosis","volume":"1","author":"Chun","year":"2012","journal-title":"Adipocyte"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski, K., Choroma\u0144ska, B., Maciejczyk, M., Dadan, J., and My\u015bliwiec, P. (2025). Modulating matrix metalloproteinase activity in obesity: Comparative effects of bariatric surgery and GLP-1\/GIP-based pharmacotherapy. J. Clin. Med., 14.","DOI":"10.20944\/preprints202509.1183.v1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"177953","DOI":"10.1016\/j.ejphar.2025.177953","article-title":"Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials","volume":"1003","author":"Miranda","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41591-024-03355-2","article-title":"Proteomic changes upon treatment with semaglutide in individuals with obesity","volume":"31","author":"Maretty","year":"2025","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1038\/s41467-024-48970-2","article-title":"Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5\/NR4a1 axis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"110635","DOI":"10.1016\/j.diabres.2023.110635","article-title":"Liraglutide demonstrates a therapeutic effect on mitochondrial dysfunction in human SGBS adipocytes in vitro","volume":"199","author":"Vaittinen","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00125-016-3933-4","article-title":"Adipose tissue plasticity: How fat depots respond differently to pathophysiological cues","volume":"59","author":"Pellegrinelli","year":"2016","journal-title":"Diabetologia"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Scavo, M.P., Lisco, G., Depalo, N., Rizzi, F., Volpe, S., Arr\u00e8, V., Carrieri, L., Notarnicola, M., De Nunzio, V., and Curri, M.L. (2024). Semaglutide modulates extracellular matrix production of LX-2 cells via exosomes and improves metabolic dysfunction-associated steatotic liver disease (MASLD). Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031493"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.beem.2013.02.005","article-title":"Adipose tissue dysfunction contributes to obesity related metabolic diseases","volume":"27","year":"2013","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI92035","article-title":"Inflammatory mechanisms linking obesity and metabolic disease","volume":"127","author":"Saltiel","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2013.12.012","article-title":"What we talk about when we talk about fat","volume":"156","author":"Rosen","year":"2014","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the SEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"152822","DOI":"10.1016\/j.bbrc.2025.152822","article-title":"GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance","volume":"14","author":"Ngabea","year":"2025","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1172\/JCI129187","article-title":"Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome","volume":"129","author":"Kahn","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","article-title":"Metabolically healthy obesity","volume":"41","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13098-025-01635-6","article-title":"Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Mousavi","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1111\/dom.15464","article-title":"Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial","volume":"26","author":"Gullaksen","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Le Magueresse-Battistoni, B. (2020). Adipose tissue and endocrine-disrupting chemicals: Does sex matter?. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249403"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:16:01Z","timestamp":1769415361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":73,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031186"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031186","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}